Literature DB >> 24185430

Attitudes toward Web application supporting pharmacist-clinician comanagement of postexposure prophylaxis patients.

Crystal M Fuller, Alezandria K Turner, Diana Hernández, Alexis V Rivera, Silvia Amesty, Michael D Lewis, Stuart Feldman.   

Abstract

OBJECTIVES: To qualitatively explore clinician and pharmacist attitudes toward using a Web application virtual pharmacist-clinician partnership (VPCP) to assist with comanaged care of illicit drug-using patients prescribed postexposure prophylaxis (PEP).
DESIGN: Qualitative, descriptive, nonexperimental study.
SETTING: New York City (NYC) from February 2011 to March 2012. PARTICIPANTS: Four pharmacists and nine clinicians. INTERVENTION: In-depth interviews. MAIN OUTCOME MEASURES: Potential impact of the VPCP on pharmacist-clinician communication and potential barriers to use of the VPCP when comanaging PEP patients among pharmacists and clinicians.
RESULTS: Pharmacists and clinicians were supportive of an interactive Web application that would expand the role of pharmacists to include assistance with PEP access and patient management. Participants noted that the VPCP would facilitate communication between pharmacists and clinicians and have potential to support adherence among patients. Pharmacists and clinicians were concerned about not having time to use the VPCP and security of patient information on the site. Pharmacist and clinician concerns informed final development of the VPCP, including creation of a user-friendly interface, linkage to users' e-mail accounts for timeline notification, and attention to security.
CONCLUSION: Use of Web-based technology to support communication between pharmacists and clinicians was seen as being a potentially feasible method for improving patient care, particularly in the delivery of PEP to drug users and other high-risk groups. These findings highlight the need for further study of a technology-supported partnership, particularly for comanagement of patients who face challenges with adherence.

Entities:  

Mesh:

Year:  2013        PMID: 24185430      PMCID: PMC3899846          DOI: 10.1331/JAPhA.2013.12208

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  28 in total

1.  Pharmacy and 20 years of AIDS.

Authors:  C R Talley
Journal:  Am J Health Syst Pharm       Date:  2001-08-01       Impact factor: 2.637

2.  Emergency prophylaxis following needle-stick injuries and sexual exposures: results from a survey comparing New York Emergency Department practitioners with their national colleagues.

Authors:  Roland C Merchant; Reza Keshavarz
Journal:  Mt Sinai J Med       Date:  2003-10

3.  A novel combination HIV prevention strategy: post-exposure prophylaxis with contingency management for substance abuse treatment among methamphetamine-using men who have sex with men.

Authors:  Raphael J Landovitz; Jesse B Fletcher; Galina Inzhakova; Jordan E Lake; Steven Shoptaw; Cathy J Reback
Journal:  AIDS Patient Care STDS       Date:  2012-06       Impact factor: 5.078

4.  Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.

Authors:  J O Kahn; J N Martin; M E Roland; J D Bamberger; M Chesney; D Chambers; K Franses; T J Coates; M H Katz
Journal:  J Infect Dis       Date:  2001-02-01       Impact factor: 5.226

5.  Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).

Authors:  R A Otten; D K Smith; D R Adams; J K Pullium; E Jackson; C N Kim; H Jaffe; R Janssen; S Butera; T M Folks
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.

Authors:  Steven D Pinkerton; Jeffrey N Martin; Michelle E Roland; Mitchell H Katz; Thomas J Coates; James O Kahn
Journal:  Arch Intern Med       Date:  2004-01-12

7.  The role of sexual transmission of HIV infection among injection and non-injection drug users.

Authors:  Steffanie A Strathdee; Susan G Sherman
Journal:  J Urban Health       Date:  2003-12       Impact factor: 3.671

8.  Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV.

Authors:  Mauro Schechter; Regina F do Lago; Aaron B Mendelsohn; Ronaldo I Moreira; Lawrence H Moulton; Lee H Harrison
Journal:  J Acquir Immune Defic Syndr       Date:  2004-04-15       Impact factor: 3.731

9.  Consortium recommendations for advancing pharmacists' patient care services and collaborative practice agreements.

Authors: 
Journal:  J Am Pharm Assoc (2003)       Date:  2013 Mar-Apr

10.  Use of non-occupational post-exposure prophylaxis does not lead to an increase in high risk sex behaviors in men who have sex with men participating in the EXPLORE trial.

Authors:  Deborah Donnell; Matthew J Mimiaga; Kenneth Mayer; Margaret Chesney; Beryl Koblin; Thomas Coates
Journal:  AIDS Behav       Date:  2010-10
View more
  3 in total

1.  Examining the Multilevel Barriers to Pharmacy-Based HIV Prevention and Treatment Services.

Authors:  Natalie D Crawford; Crystal F Lewis; Ronnie Moore; Glen Pietradoni; Paul Weidle
Journal:  Sex Transm Dis       Date:  2022-05-12       Impact factor: 3.868

2.  The Role of Pharmacies in the HIV Prevention and Care Continuums: A Systematic Review.

Authors:  Natalie D Crawford; Sky Myers; Henry Young; Donald Klepser; Elyse Tung
Journal:  AIDS Behav       Date:  2021-01-02

3.  Acceptability and feasibility of a pharmacist-led HIV pre-exposure prophylaxis (PrEP) program in the Midwestern United States.

Authors:  Joshua P Havens; Kimberly K Scarsi; Harlan Sayles; Donald G Klepser; Susan Swindells; Sara H Bares
Journal:  Open Forum Infect Dis       Date:  2019-10-01       Impact factor: 3.835

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.